Tariff exposure and less predictable supply chains have pushed many international medical device developers and life sciences teams to take a second look at where their products are actually made. For companies currently manufacturing in cost-advantaged markets overseas, the U.S. is increasingly part of that conversation, not only as a distribution destination but as a production location.
Moving clean room manufacturing into the U.S., whether that means standing up a new site, or transferring an existing production line to a qualified U.S. partner, is a different exercise than opening a new market. The regulatory environment, quality system expectations, and supply chain conditions here don’t map cleanly onto what most international teams are used to. This guide is for teams outside the U.S. weighing U.S. production, including those that plan to keep distributing to markets beyond it.
Some process and product documentation gaps are easier to anticipate than others. What’s harder to plan is how it all interconnects (quality systems, materials, equipment, workforce, and distribution plans) once production is running.
Assess Your Quality System Before Committing Capital
Before signing anything, most international teams benefit from treating this like a technology transfer, even if there’s no existing U.S. process to transfer yet. Start by confirming how U.S. and target-market health authorities will classify and regulate your product, then run a gap assessment. Compare your current quality management system to what U.S. manufacturing and distribution will expect, and understand what it might take to become compliant without late-stage remediation.
The financial side deserves the same scrutiny. Material costs, supply conditions, tariff exposure, and freight look different once production shifts, and the numbers don’t always move in a linear fashion. But the full picture, including landed cost, labor, facility overhead, and the cost of getting a new site or partner qualified, is worth mapping out before committing capital.
Related Reading: Best Practices for Maintaining Continuity When Transferring Validated Processes
Don’t Underestimate What U.S. Regulatory Expectations Require
How many challenges a company faces when moving manufacturing stateside often comes down to two things: the size of the organization that owns the intellectual property (IP) and how much U.S. regulatory experience already sits inside it.
- A larger company with a dedicated regulatory affairs team will likely run into fewer surprises.
- A smaller company running on a few outside consultants, or a team that has never manufactured a product under U.S. Food & Drug Administration (FDA) oversight, tends to feel the learning curve more directly.
The requirements under the FDA’s Quality Management System Regulation (QMSR), facility registration, and state-level rules layered on top don’t always resemble what a company has managed under its home country’s framework. For drug and biologic products, current good manufacturing practice (cGMP) requirements under 21 CFR Parts 210 and 211 apply instead, and combination products must satisfy both. Without a quality and regulatory expert who has been through this specific process before, it’s easy to underestimate how much documentation and internal alignment U.S. submission pathways expect.
Know Where U.S. Practice Diverges From What You’re Used To
For teams that also plan to distribute internationally, U.S. requirements are only part of the picture, which makes cross-market regulatory alignment important. Regulatory requirements vary across the European Union Medical Device Regulation (EU MDR), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and Australia’s Therapeutic Goods Administration (TGA), for example, even where quality-system expectations have become more harmonized. Companies planning multi-market distribution should account for those differences early rather than assuming that compliance in one market will fully satisfy another.
Since February 2026, the QMSR has aligned 21 CFR 820 with ISO 13485, giving the U.S. medical device industry a more consistent quality system language to work from. That alignment helps, but it doesn’t resolve every difference, particularly for combination products, where the therapeutic and device constituent parts each carry their own regulatory expectations, and the product must satisfy more than one framework at once.
Novel technology adds complexity here, because classification drives which regulatory requirements and pathway applies.
When no established pathway or precedent to market exists, experience with FDA-regulated and international programs can become particularly valuable, especially when the product has a novel technology, manufacturing process, or regulatory pathway. Where an application-based inspection is applicable, manufacturers should be prepared to demonstrate that their facility, processes, controls, and records support the information provided to FDA and the consistent manufacture of the product.
Plan for Supply Chain and Workforce Realities Early
Supply chain realities can feel secondary to assessing process repeatability and production consistency, but they can quickly disrupt a project timeline. It’s worth establishing dual sourcing or a qualified backup supplier where feasible. However, for custom or specialized materials, a second source isn’t always available, and a single-source material can set the pace of the entire transfer. Material availability in the U.S. can differ from what your team sourced elsewhere, and importing through U.S. customs adds its own timeline variability.
Workforce availability tends to be less of a bottleneck than materials, and skilled labor is often easier to find in areas with an established manufacturing presence, though that’s not something to take for granted without confirming it for the specific process in front of you. The harder question is whether the site you’re evaluating has the right skill sets for your process. Rather than assuming anything from a facility tour or preliminary conversations, confirm specialized manufacturing capabilities directly with a prospective CDMO.
Choose a Partner That Can Scale Manufacturing Plans With Your Program Goals
Look for a manufacturing partner willing to grow with the product and processes in place now, not one that only takes it on once it’s already commercial-ready. Engaging a CDMO earlier can help teams plan required transfer, qualification, and validation activities before manufacturing decisions become difficult or costly to change. That typically requires:
- Documentation practices that satisfy both U.S. and international expectations
- Familiarity with import and export handling for materials and components crossing borders
- Sufficient internal regulatory depth and experience
Ascential regularly works with medical device and life sciences companies moving implantable, consumable, and combination product manufacturing into the U.S.
If your team is exploring whether U.S.-based clean room manufacturing makes sense for your program’s long-term goals, a short conversation with Ascential’s Ham Lake, Minnesota facility team can inform your next strategic investment. From quality and regulatory requirements to application engineering, automation, and manufacturing needs, that conversation can clarify what a right-sized path to the U.S. would actually involve.